These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
404 related articles for article (PubMed ID: 17296738)
1. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen. von Hentig N; Müller A; Rottmann C; Wolf T; Lutz T; Klauke S; Kurowski M; Oertel B; Dauer B; Harder S; Staszewski S Antimicrob Agents Chemother; 2007 Apr; 51(4):1431-9. PubMed ID: 17296738 [TBL] [Abstract][Full Text] [Related]
2. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation. Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S Clin Infect Dis; 2007 Jun; 44(11):1475-83. PubMed ID: 17479946 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers. King JR; Kakuda TN; Paul S; Tse MM; Acosta EP; Becker SL J Clin Pharmacol; 2007 Feb; 47(2):201-8. PubMed ID: 17244771 [TBL] [Abstract][Full Text] [Related]
4. Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients. Seminari E; Guffanti M; Villani P; Gianotti N; Cusato M; Fusetti G; Galli A; Castagna A; Regazzi M; Lazzarin A Eur J Clin Pharmacol; 2005 Aug; 61(7):545-9. PubMed ID: 16041598 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses. Boffito M; Maitland D; Dickinson L; Back D; Hill A; Fletcher C; Moyle G; Nelson M; Gazzard B; Pozniak A AIDS Res Hum Retroviruses; 2006 Aug; 22(8):749-56. PubMed ID: 16910830 [TBL] [Abstract][Full Text] [Related]
7. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. Veldkamp AI; van Heeswijk RP; Mulder JW; Meenhorst PL; Schreij G; van der Geest S; Lange JM; Beijnen JH; Hoetelmans RM J Acquir Immune Defic Syndr; 2001 Aug; 27(4):344-9. PubMed ID: 11468422 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen. Boffito M; Dickinson L; Hill A; Back D; Moyle G; Nelson M; Higgs C; Fletcher C; Mandalia S; Gazzard B; Pozniak A Antivir Ther; 2004 Jun; 9(3):423-9. PubMed ID: 15259905 [TBL] [Abstract][Full Text] [Related]
9. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394 [TBL] [Abstract][Full Text] [Related]
10. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709 [TBL] [Abstract][Full Text] [Related]
11. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects. Cardiello PG; Monhaphol T; Mahanontharit A; van Heeswijk RP; Burger D; Hill A; Ruxrungtham K; Lange JM; Cooper DA; Phanuphak P J Acquir Immune Defic Syndr; 2003 Apr; 32(4):375-9. PubMed ID: 12640194 [TBL] [Abstract][Full Text] [Related]
13. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women. Conradie F; Zorrilla C; Josipovic D; Botes M; Osiyemi O; Vandeloise E; Eley T; Child M; Bertz R; Hu W; Wirtz V; McGrath D HIV Med; 2011 Oct; 12(9):570-9. PubMed ID: 21569187 [TBL] [Abstract][Full Text] [Related]
14. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study. Cardiello PG; van Heeswijk RP; Hassink EA; Srasuebkul P; Mahanontharit A; Samor TM; Worarien W; Beijnen JH; Hoetelmans RM; Ruxrungtham K; Cooper DA; Lange JM; Phanuphak P J Acquir Immune Defic Syndr; 2002 Apr; 29(5):464-70. PubMed ID: 11981362 [TBL] [Abstract][Full Text] [Related]
15. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir. Kurowski M; Müller M; Donath F; Mrozikiewicz M; Möcklinghoff C Eur J Med Res; 1999 Mar; 4(3):101-4. PubMed ID: 10085276 [TBL] [Abstract][Full Text] [Related]
16. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166 [TBL] [Abstract][Full Text] [Related]
17. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898 [TBL] [Abstract][Full Text] [Related]
18. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures. Colombo S; Buclin T; Franc C; Guignard N; Khonkarly M; Tarr PE; Rochat B; Biollaz J; Telenti A; Decosterd LA; Cavassini M Antivir Ther; 2006; 11(1):53-62. PubMed ID: 16518960 [TBL] [Abstract][Full Text] [Related]
19. [Comparison of pharmacokinetics of saquinavir soft-gel capsule (SQV-SGC) combined with ritonavir (RTV), SQV hard-gel capsule with RTV, and SQV-SGC alone]. Tsuchiya K; Hirabayashi Y; Imai K; Kikuchi Y; Tachikawa N; Genka I; Teruya K; Yasuoka A; Oka S; Kimura S Kansenshogaku Zasshi; 2003 Jun; 77(6):436-42. PubMed ID: 12872693 [TBL] [Abstract][Full Text] [Related]
20. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study). Lamotte C; Landman R; Peytavin G; Mentre F; Gerbe J; Brun-Vezinet F; Boue F; Spiridon G; Valantin MA; Michelet C; Farinotti R; Yeni P Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]